// App-Quantinova.ai

875 : Next generation clonal neoantigen targeting T cells, generated using the PELEUSTM bioinformatics platform and the VELOSTM manufacturing method show superior reactivity and phenotypic characteristics than classical TIL products

Researchers

Presenter

  • Eleni Kotsiou

Principal Investigators

  • Joseph Robinson

  • Sonal Varsani

  • Theres Oakes

  • Pablo D. Becker

  • Shreenal Patel

  • Jennine Mootien

  • Andrew Craig

  • Jane Robertson

  • Edward Samuel

  • James Reading

  • Lyra Del Rosario

  • Andrew Haynes

  • Samra Turajlic

  • Farah Islam

  • David Lawrence

  • Mariam Jamal-Hanjani

  • Martin Foster

  • Sergio A. Quezada

  • Katy Newton

Medical Centers

  • Achilles Therapeutics Limited, Stevenage, United Kingdom

  • University College London Hospitals/UCL Cancer Institute, London, United Kingdom

  • The Royal Marsden Hospital NHS Foundation Trust, London & Surrey, United Kingdom

  • UCLH and Barts NHS Trusts, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Melanoma

  • Non Small Cell Lung cancer

Biomarkers

  • Cluster of Differentiation 4

  • Cluster of differentiation 8A

  • Interleukin-2

Drug/Treatment

  • N/A

Outcome

  • N/A

Study Design

  • First-In-Human

Phase

  • NA

Study Id's

  • NCT03517917

  • NCT04032847

  • NCT03997474

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved